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Drug tolerance in bacteria is widely believed to be due to metabolic changes that accompany
growth arrest. A study in this issue of Cell reveals a drug tolerance mechanism in replicating
mycobacteria that is induced by residence in macrophages and depends on drug efflux.In the context of tuberculosis (TB), directly
observed therapy involves a trained
observer watching patients take their TB
medications inorder to improveadherence
and achieve a cure. In this issue of Cell,
Adams and Takaki and colleagues (Adams
et al., 2011) bring newmeaning to the term
‘‘directly observed therapy’’ by using
transparent zebrafish embryos to study
the response of Mycobacterium marinum
to antimycobacterial drugs. In doing so,
they discover an unsuspectedmechanism
for thephenomenonof bacterial drug toler-
ance. Bacterial drug tolerance is less well
understood than drug resistance, but
both limit the successful treatment of
many bacterial infections. Bacterial resis-
tance occurs due to selection of geneti-
cally mutant, drug-resistant bacteria,
some of which are resistant to multiple
drugs and can be difficult or impossible
to treat. In contrast, drug-tolerant bacteria,
also known as persisters in certain con-
texts, are phenotypically resistant to anti-
microbial drugs yet genetically identical
to drug-susceptible bacteria in the same
population. The importance of drug toler-
ance is substantial, as it contributes to
treatment failures, allows for the emer-
gence of genetic drug resistance, and
necessitates prolonged treatment courses
that can be costly, toxic, and difficult for
patients to complete. A classic and espe-
cially important example of drug tolerance
occurs in tuberculosis, whose cure
currently requires a minimum of 6 months
of multiple antimicrobial drugs.In many cases, drug tolerance is
observed in vitro as a biphasic curve of
bacterial killing: upon addition of an active
drug, there is a rapid exponential de-
crease in the number of viable bacteria,
followed by a slower decrease with pro-
longed persistence of viable bacteria.
Characterization of the bacteria that
remain viable reveals that they retain the
drug susceptibility of the original popula-
tion, yet they have survived in the pres-
ence of otherwise lethal concentrations
of drug. In one especially well-character-
ized system, the drug-tolerant persisters
are in an arrested growth state (Balaban
et al., 2004) due to stochastic fluctuations
of expression in a specific bacterial toxin-
antitoxin pair, in which higher expression
of the toxin protein causes growth arrest
(Rotem et al., 2010). It is widely believed
that a general property of drug-tolerant
bacteria is that they are growing slowly
or not at all and that the metabolic
changes that accompany growth arrest
account for the inability to be killed by
standard antimicrobial drugs.
In this issue of Cell (Adams et al., 2011),
Adams and Takaki and colleagues pro-
vide evidence for a new model of drug
tolerance inmycobacteria (Figure 1). First,
they find that drug-tolerant bacteria need
not be in a growth-arrested state. By
directly observing fluorescent Mycobac-
terium marinum in transparent zebrafish
embryos, they determine that a subpopu-
lation of bacteria continues to replicate at
the same time that the majority of bacteriaCeare killed by antimycobacterial drugs.
Second, they find that uptake and resi-
dence in macrophages provide the signal
for induction of drug tolerance. Drug-
tolerant bacteria were observed very early
after infection of zebrafish embryos, but
tolerance did not occur in embryos that
are deficient in macrophages due to
knockdown of the PU.1 transcription
factor. In addition, drug tolerance in
M. marinum and M. tuberculosis was
enhanced by intracellular growth in cul-
tured murine and human macrophages.
Of note, the tolerant phenotype was
detectable up to 5 days following release
from macrophages, indicating that extra-
cellular mycobacteria can exhibit toler-
ance if they have recently resided within
a macrophage. Third, the investigators
find that the newly discovered mecha-
nism of tolerance is attributable to bacte-
rial efflux pumps whose expression is
induced upon macrophage entry, and at
least one of these efflux pumps is essen-
tial for optimum mycobacterial survival in
macrophages, even in the absence of
drug. Inducible drug efflux pumps con-
tribute to drug resistance in many con-
texts, from multidrug-resistant bacteria
to tumor cell resistance to chemotherapy.
Indeed, efflux pumps have been impli-
cated in drug-induced drug tolerance in
M. tuberculosis. The observation that
bacterial efflux pumps can be induced
by intracellular localization and contribute
to drug tolerance in actively replicating
mycobacteria is an especially notablell 145, April 1, 2011 ª2011 Elsevier Inc. 13
Figure 1. Antibiotic Tolerance in Replicating Mycobacteria Mediated by Macrophage-
Induced Drug Efflux
(A) Extracellular mycobacteria are killed and eliminated by antibiotics.
(B) Mycobacteria that enter macrophages may retain susceptibility to drugs and be killed, or they may
induce expression of efflux pumps, which makes them drug tolerant and able to replicate and persist in
the face of otherwise lethal concentrations of antibiotics. Dashed arrows indicate potential fates of
mycobacteria; solid arrows indicate the direction of drug accumulation in individual bacteria.contribution that will surely stimulate
further investigation.
The observations reported by Adams
and Takaki and colleagues provoke
numerous questions. First, what fraction
of mycobacterial drug tolerance can be
attributed to the macrophage-induced
efflux pump mechanism? This is a crucial
question, as development of new treat-
ment approaches to TB will depend on
the answer. If drug efflux is the major
mechanism of tolerance of M. tubercu-
losis in human infections, then inhibitors
of efflux should have a significant treat-
ment-shortening effect, which is currently
one of the major goals of TB drug devel-
opment efforts (Salomon et al., 2006).
On the other hand, if nonreplicating
bacteria also make a significant contribu-14 Cell 145, April 1, 2011 ª2011 Elsevier Inc.tion to tolerance, then efforts to develop
drugs that target nonreplicating bacteria
(Bryk et al., 2008) will also be critical. It
will be important to determine whether
inhibition of drug efflux shortens the
required duration of TB therapy, increases
cure rates, or both. Because at least one
efflux pump is required for intracellular
growth as well as tolerance, targeting
such pumps may eradicate infection by
dual mechanisms. A practical problem to
address is that it appears that distinct
pumps are used for efflux of distinct
drugs; in particular, Adams and Takaki
et al. report that verapamil reduces toler-
ance to rifampin, but not isoniazid, in
M. tuberculosis. Thus, the identification
of more efflux pump inhibitors will be
needed before it is clear whether treat-ment of TB can be improved by the addi-
tion of a single inhibitor. It will also be
important to define the macrophage
signals that induce expression of the rele-
vant bacterial efflux pumps and how
these signals are received and trans-
duced by mycobacteria. If one signal
induces multiple efflux pumps, then
targeting that signaling pathway may pro-
vide an approach to overcoming toler-
ance of multiple drugs simultaneously.
Finally, is the phenomenon of host
induction of drug tolerance a general
phenomenon in bacteria, or is it confined
to mycobacteria and other intracellular
pathogens? Because drug tolerance is
observed and prolonged courses of anti-
biotics are required in other infections,
the finding that drug tolerance can occur
in populations of replicatingmycobacteria
should prompt assessment of whether
similar principles apply to other infectious
diseases. Directly observed therapy for
TB infection in humans improves cure
rates and reduces the emergence of
drug resistance. The insight derived from
directly observed therapy in zebrafish
has the potential to make a similar contri-
bution.
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